Conditions: Hepatitis C
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 9
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and pharmacokinetics of MK-1075, and to determine the ability of MK-1075 to reduce HCV viral load, following administration of a single dose in HCV-infected participants.

Detailed description:
Per protocol, panels may be omitted if the objectives of the study are met in preceding panels.

Arms:
arm 1: HCV-infected participants receive a single 100 mg dose of MK-1075. arm 2: HCV-infected participants receive a single 200 mg dose of MK-1075. arm 3: HCV-infected participants receive a single 400 mg dose of MK-1075. arm 4: HCV-infected participants receive a single 800 mg dose of MK-1075.

Interventions: intervention 1: MK-1075
Intervention descriptions: intervention 1: MK-1075 supplied as 10 mg or 100 mg tablets for oral administration.

Protocol document: